Retention of activity by selected anthracycfines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression
1991
Activity of Anthracyclines in Drug-Resistant Lung Cancer Cells
publication
Author Information
Author(s): H.M. Coley, P. Workman, P.R. Twentyman
Primary Institution: MRC Clinical Oncology and Radiotherapeutics Unit
Hypothesis
Can selected anthracyclines retain activity in a multidrug resistant human lung carcinoma line that does not express P-glycoprotein?
Conclusion
Selected anthracyclines can still be effective in a specific type of drug-resistant lung cancer cells.
Supporting Evidence
- The COR-L23/R subline shows cross-resistance to several drugs but does not express P-glycoprotein.
- COR-L23/R has reduced accumulation of doxorubicin and daunorubicin compared to the parental cell line.
- The efflux of daunorubicin in COR-L23/R is enhanced and energy-dependent.
Takeaway
Some cancer cells can resist drugs, but certain modified drugs can still work against them.
Methodology
The study involved examining a subline of lung cancer cells for drug resistance and drug accumulation.
Want to read the original?
Access the complete publication on the publisher's website